Avoid common mistakes on your manuscript.
Correction: PharmacoEconomics - Open https://doi.org/10.1007/s41669-023-00420-3
Upon publication of the original manuscript (Bromilow 2023), the authors noticed an error in the Abstract and an error in the Key Points for Decision Makers section. The following corrections were requested:
The first sentence of the Conclusion section of the Abstract should read as follows: ‘First-line vancomycin and second-line fidaxomicin was the most cost-effective treatment sequence at the NICE threshold for treating CDI in England’.
The second Key Point for Decision Makers should read as follows: ‘The cost-effectiveness model compared different sequences of interventions for the treatment of CDI in the UK and, after certain sequences were excluded by the committee, found that vancomycin followed by fidaxomicin was the most cost-effective sequence’.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Bromilow, T., Holmes, H., Coote, L. et al. Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England. PharmacoEconomics Open 7, 861 (2023). https://doi.org/10.1007/s41669-023-00434-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41669-023-00434-x